<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Varga, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sydney Montesi, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce S Lee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) that is often progressive and has a poor prognosis [<a href="#rid1">1-7</a>]. SSc-associated ILD consists of various histopathologic subtypes, most commonly nonspecific interstitial pneumonitis and usual interstitial pneumonitis.</p><p>The treatment and prognosis of SSc-ILD will be reviewed here. The clinical presentation and diagnosis of SSc lung disease, the treatment of SSc in general, and the treatment of SSc-associated pulmonary arterial hypertension are discussed separately. (See  <a class="medical medical_review" href="/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"</a> and  <a class="medical medical_review" href="/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TYPES OF INTERSTITIAL LUNG DISEASE</span><span class="headingEndMark"> — </span>The term interstitial lung disease (ILD) is broadly used to describe a heterogeneous group of disorders that are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations. In this topic review, we refer broadly to systemic sclerosis (SSc)-ILD and do not distinguish among the histopathologic subtypes.</p><p>In the vast majority of patients with SSc-ILD, the lung injury is characterized by a pattern termed nonspecific interstitial pneumonia (NSIP) [<a href="#rid8">8</a>]. Histopathologically, NSIP is characterized by varying degrees of pulmonary inflammation and fibrosis, with some forms being primarily inflammatory (cellular NSIP) and others primarily fibrotic (fibrotic NSIP). Patients with a more fibrosing form of NSIP have worse outcomes compared with those with cellular NSIP [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia"</a> and  <a class="medical medical_review" href="/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Nonspecific interstitial pneumonia'</a>.)</p><p>A minority of patients with SSc-ILD have the histopathologic pattern of UIP [<a href="#rid8">8</a>], the characteristic pattern associated with idiopathic pulmonary fibrosis (IPF). This pattern is characterized by the presence of scattered foci of fibroblast proliferation ("fibroblast foci"), nonuniform distribution of areas of dense fibrosis, scant inflammation, and honeycomb change. While histopathologic pattern of usual interstitial pneumonia (UIP) is less common than NSIP in connective tissue-associated ILD, when present a UIP pattern (histopathologically or radiographically) confers a worse survival compared to NSIP [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">INITIATING THERAPY</span><span class="headingEndMark"> — </span>The optimal treatment for systemic sclerosis-associated interstitial lung disease (SSc-ILD) is not known. Based on the best available evidence, we suggest initiating immunosuppressive therapy in patients with symptomatic SSc-ILD and features suggesting a high likelihood of progression. <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil is preferred as initial therapy over <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> due to a better safety profile and comparable efficacy as described in the following sections. <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> is an alternative that can be considered for patients with contraindications to or intolerance of cyclophosphamide and mycophenolate. Patients can also be offered the opportunity to participate in a clinical trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fsearch%3Fterm%3Dsystemic+sclerosis&amp;token=UoHczUsItwyR3oazzB10tzdVbvf2EAVV2j%2BS2f3TwmCZtZ1pJAROcTJgW348fVqlszT3NljrHVhj1XstvY70SRYkVy5h3N1jCF3YtpNekzo%3D&amp;TOPIC_ID=4375" target="_blank">clinicaltrials.gov</a>). </p><p class="headingAnchor" id="H2004469349"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Exact criteria for initiation of immunosuppressive treatment for SSc-ILD have not been established, and the decision about initiating therapy can be difficult because the benefits of therapy appear to be modest and the toxicities significant. As many patients with SSc-ILD have stable or slowly progressive disease, selection of appropriate therapy requires a balance between avoiding potentially toxic agents in these patients, while providing therapy to those most likely to progress. Features that are associated with progression of lung disease are listed in the table and described below  (<a class="graphic graphic_table graphicRef105688" href="/d/graphic/105688.html" rel="external">table 1</a>). </p><p>It is thought that patients are more likely to benefit from therapy when it is initiated early in the course of disease, before a substantial loss of lung function has occurred [<a href="#rid12">12-16</a>]. In approximately half of the patients with progressive SSc ILD, the most rapid decline in forced vital capacity (FVC) occurs within the initial three years of disease onset, indicating that lung injury and fibrosis may be early complications [<a href="#rid13">13</a>]. </p><p>Features associated with ILD progression include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of ILD</strong> – Based on observational data, patients with early SSc-ILD are more likely to have active inflammation and to respond to pharmacologic intervention with immunosuppressive agents than those with long-standing disease [<a href="#rid17">17</a>]. Although there is no uniform agreement on how early disease should be defined, it generally refers to the initial 12 to 24 months of SSc disease before significant irreversible organ fibrosis is established. However, results from the Scleroderma Lung Study (SLS1) showed that in some patients with SSc-ILD, lung disease can show progression even when present for more than four years [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary function</strong> – No specific pulmonary function test (PFT) values have been validated in SSc-ILD, as triggers for initiating therapy. Serial tests that demonstrate worsening pulmonary function (eg, a ≥10 percent decline in FVC or diffusing capacity for carbon monoxide [DLCO]) are an indication of active disease for which treatment initiation should be considered. Pulmonary function tests demonstrating a restrictive ventilatory defect (ie, reduced total lung capacity, often accompanied by a reduced FVC with a preserved forced expiratory volume in one second [FEV<sub>1</sub>] to FVC ratio) and decreased DLCO are consistent with SSc-ILD. However, as noted above, a proportion of patients with SSc-ILD will have normal pulmonary function despite HRCT evidence of ILD [<a href="#rid19">19</a>]. A retrospective analysis of 80 patients with SSc-ILD from the Royal Brompton Hospital (London, United Kingdom) showed that mortality increased with decreasing initial FVC levels and decreasing initial DLCO levels [<a href="#rid8">8</a>]. Characteristic findings on PFTs are described separately. (See  <a class="medical medical_review" href="/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Pulmonary function testing'</a>.)</p><p></p><p class="bulletIndent1">Follow-up of patients enrolled in the Scleroderma Lung Studies (SLS) I and II has shown that short-term progression of ILD was a better predictor of mortality than baseline severity of ILD, in particular, patients who experienced a decline in the FVC and DLCO over two years had a substantially increased risk of mortality even after adjusting for treatment arm assignment, as well as baseline disease severity [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-resolution computed tomography (HRCT) </strong>– The proportion of lung affected by ILD can be assessed by HRCT and appears to predict disease progression and mortality  (<a class="graphic graphic_diagnosticimage graphicRef70357" href="/d/graphic/70357.html" rel="external">image 1</a>). The presence of radiologic lung fibrosis in SSc patients at baseline confers an increased risk of mortality even among those with a preserved forced vital capacity [<a href="#rid21">21</a>]. In one study, radiographic changes affecting &gt;20 percent of the lung were shown to be predictors of greater mortality [<a href="#rid22">22</a>]. A subsequent study of 172 patients confirmed these results [<a href="#rid15">15</a>]. The finding of widespread honeycombing with SSc-ILD, suggests advanced fibrosis that is unlikely to respond to immunosuppressive therapy. Focal lung scarring, especially in the posterior lung fields, and tree-in-bud opacities may suggest recurrent aspiration that should be treated with measures to prevent aspiration. The typical HRCT findings of SSc-ILD are described separately. (See  <a class="medical medical_review" href="/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk prediction model</strong> – It has been shown that three-year mortality risk in SSc-ILD can be estimated using the SADL model (ever Smoking history, Age, and percent predicted Diffusing capacity of the Lung for carbon monoxide) developed in two independent cohorts of patients with SSc-ILD with a total of 225 patients [<a href="#rid23">23</a>].</p><p></p><p>We do not use the results of bronchoalveolar lavage cell counts to determine the likelihood of response to immunosuppressive therapy, despite earlier small studies that suggested a correlation [<a href="#rid24">24-27</a>]. Similarly, we do not obtain a lung biopsy to determine the histopathology unless unusual features are present, as the majority of patients with SSc-ILD have fibrotic nonspecific interstitial pneumonitis and current treatment is not based on pathologic subtypes. </p><p class="headingAnchor" id="H2656629032"><span class="h2">Choice of initial agent</span><span class="headingEndMark"> — </span>Once the decision has been made to initiate therapy for ILD, we suggest using <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) rather than <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> as initial therapy, based on evidence of comparable efficacy and a better adverse effect profile for MMF. This was illustrated in the Scleroderma Lung Study II (SLS II) that compared MMF with cyclophosphamide and found no significant differences in lung function, but better tolerance of MMF [<a href="#rid28">28</a>]. The details are described below. (See <a class="local">'Efficacy'</a> below and  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> is approved by the US Food and Drug Administration (FDA) for slowing the rate of decline in pulmonary function in patients with SSc-ILD and has a good safety profile. Tocilizumab can be considered as an alternative to <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> for initial therapy. <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> is inferior to <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and is generally only used if other initial therapies are not tolerated. (See <a class="local">'Alternative initial pharmacologic therapy'</a> below.)</p><p class="headingAnchor" id="H1942183165"><span class="h2">Mycophenolate mofetil</span><span class="headingEndMark"> — </span>MMF is an inhibitor of T and B lymphocyte proliferation that is often used in the treatment of extrapulmonary manifestations of SSc and other rheumatic diseases. Based on results from the SLS II trial described above that compared MMF with oral <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, we suggest MMF as first line therapy in patients with SSc-ILD who are at risk for progressive ILD [<a href="#rid28">28</a>]. (See <a class="local">'Choice of initial agent'</a> above.)</p><p class="headingAnchor" id="H1153184496"><span class="h3">Dose and duration</span><span class="headingEndMark"> — </span>The target dose of MMF is generally between 1.5 and 3 g daily, usually given in two divided doses [<a href="#rid28">28</a>]. Starting with lower doses may enhance gastrointestinal tolerance of MMF. The SLS II clinical trial used a designated dose escalation schedule starting at 500 mg twice daily and increasing to the target dose of 1.5 g twice daily over three to four months [<a href="#rid28">28</a>].</p><p>The maximal dose of MMF should be reduced in patients with end-stage kidney disease. A number of drug interactions can affect serum concentrations. In particular, proton pump inhibitors and antacids, which are very commonly used in SSc, and mineral supplements can interfere with MMF absorption. Dosing of antacids and mineral supplements should be separated from MMF by least two hours. Dosing and potential drug interactions of MMF are described separately. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Mycophenolate dose and administration'</a> and  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a>.)</p><p>The optimal duration of MMF therapy is unknown. In the Scleroderma Lung Study II, treatment with MMF was continued for 24 months, but most experts, including us, continue MMF for several years as maintenance therapy in patients who show stabilization of lung function. (See <a class="local">'Maintenance therapy'</a> below.)</p><p class="headingAnchor" id="H4190242825"><span class="h3">Monitoring and adverse effects</span><span class="headingEndMark"> — </span>Bone marrow suppression and gastrointestinal (GI) symptoms are the most commonly observed adverse effects. A complete blood count should be performed one to two weeks after the start of therapy and periodically during dose escalation. If there is no evidence of bone marrow suppression, it is our practice to check complete blood counts every six to eight weeks and gradually extend the period. Gastrointestinal symptoms, such as nausea, diarrhea, and abdominal cramping, are frequent, but may improve with divided dosing (eg, three to four times a day) or a reduction in the total daily dose. Enteric-coated <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> sodium may be an option but requires dose adjustment. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Adverse effects'</a>.)</p><p>Because MMF is associated with an increased risk of miscarriage and congenital anomalies, it should be avoided during pregnancy. Reliable contraception should be employed by women of child-bearing potential. MMF is excreted in breast milk and is contraindicated in lactating women. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Mycophenolate mofetil'</a>.)</p><p>Pneumocystis prophylaxis is generally not necessary during MMF therapy unless there are other indications. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Pneumocystis jirovecii'</a>.)</p><p class="headingAnchor" id="H633681534"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The role of MMF in SSc-ILD has been assessed in a randomized trial (SLS II), retrospective reviews, and small prospective case series [<a href="#rid28">28-41</a>]. The consistent finding is of modest improvement or stabilization in lung function and dyspnea. (See  <a class="medical medical_review" href="/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Other immunosuppressive agents'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>SLS II was a randomized trial that included 142 patients with SSc-ILD, characterized by a forced vital capacity (FVC) &lt;80 percent, but &gt;45 percent of predicted, exertional dyspnea, ground glass opacities on HRCT with or without reticular opacities, and onset of the first non-Raynaud symptom of SSc within the prior seven years [<a href="#rid28">28</a>]. Participants were assigned to MMF 1500 mg twice daily for 24 months or oral <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> titrated up to a maximum daily dose of 1.8 to 2.3 mg/kg for 12 months. Both groups demonstrated improvement in adjusted percent predicted FVC from baseline to 24 months: 2.19 percent (95% CI 0.53-3.84) in the MMF group and 2.88 percent (95% CI 1.19-4.58) in the cyclophosphamide group, a nonsignificant difference. Dyspnea improved in both groups based on the Transition Dyspnea Index [<a href="#rid42">42</a>]. MMF was better tolerated than cyclophosphamide based on a longer time to patient withdrawal and a lower incidence of leukopenia and thrombocytopenia. Longer-term toxicities of cyclophosphamide, including gonadal toxicity, hemorrhagic cystitis, and malignancies, were not assessed in the trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Forty-one patients with mild SSc-ILD (FVC ≥70 percent predicted) were randomly assigned to MMF at a total dose of 2 g per day or placebo for 6 months. While the modified Rodnan skin score (mRSS) improved with MMF, dyspnea, DLCO, and 6MWT were similar between groups [<a href="#rid41">41</a>]. Additional study is needed given the small size and short duration of this trial. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two retrospective reviews of a combined total of 30 patients with SSc-ILD, MMF treatment for up to 24 months was associated with improved or stable pulmonary function relative to baseline [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small observational studies (total of 39 patients) reported stability or improvement in lung function after initiation of MMF or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> sodium (MS) [<a href="#rid29">29,32,38</a>].</p><p></p><p class="headingAnchor" id="H2542314703"><span class="h2">Alternative initial pharmacologic therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> are alternative initial immunosuppressive agents for patients with SSc-ILD. Compared with placebo, tocilizumab has been shown to reduce lung function decline. Cyclophosphamide itself has been established to have similar efficacy to MMF but has significantly higher toxicity. Azathioprine likely results in inferior outcomes but has been used for many years in patients with SSc-ILD who were felt not appropriate for or did not tolerate other agents.</p><p class="headingAnchor" id="H3482795336"><span class="h3">Tocilizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> is a humanized anti-interleukin (IL)-6 receptor antibody of the IgG1 subclass that is used in the treatment of rheumatoid arthritis, giant cell arteritis, and polyarticular juvenile idiopathic arthritis. In SSc, elevated circulating IL-6 is predictive of the progression of ILD, suggesting potential therapeutic benefit to IL-6 antagonism [<a href="#rid43">43</a>]. Based on results from the clinical trials described below, tocilizumab has been approved in the United States for slowing the rate of decline in pulmonary function in adults with SSc-ILD [<a href="#rid44">44</a>]. Tocilizumab is not used to treat SSc skin disease. Tocilizumab has not been directly compared with MMF. While awaiting additional data, tocilizumab is a reasonable treatment alternative to MMF as initial therapy in patients with early diffuse SSc and ILD, particularly in those who are unable to take MMF and have early evidence of ILD progression or prominent musculoskeletal involvement. Tocilizumab is also a reasonable alternative in those with elevated acute phase reactants (eg, platelets and CRP), as it is effective in decreasing these measures; however, we recognize that acute phase reactants are only surrogates of disease activity and that there are no data regarding tocilizumab efficacy specifically in this patient subset.</p><p class="headingAnchor" id="H1021058607"><span class="h4">Dose and administration</span><span class="headingEndMark"> — </span>For patients with SSc-ILD, the dose of <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> is 162 mg once every week, given subcutaneously. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Tocilizumab'</a>.)</p><p class="headingAnchor" id="H877589005"><span class="h4">Monitoring and adverse effects</span><span class="headingEndMark"> — </span>Patients should be screened for late<em>nt Mycobacterium tuberculosis</em> infection prior to initiation of <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>. A complete blood count, alanine aminotransferase (ALT)/aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin should be obtained prior to therapy, four to eight weeks after start of therapy, and every three months thereafter. Use of tocilizumab is not advised during pregnancy.</p><p>The most common adverse effects associated with <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> are upper respiratory infection, headache, hypertension, elevated alanine aminotransferase, and injection site reactions. Interruption of dosing may be needed for laboratory abnormalities such as neutropenia, thrombocytopenia, or elevated liver enzymes. Live vaccines should be avoided during tocilizumab therapy. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Tocilizumab'</a>.)</p><p class="headingAnchor" id="H287088983"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Two randomized trials evaluating <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> versus placebo demonstrated benefit in lung function with treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>An interim report of the randomized clinical trial (faSScinate) of subcutaneous <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> versus placebo for SS skin disease suggested potential benefit in slowing a modest reduction in the decline in forced vital capacity (FVC) at 24 weeks, but not 48 weeks [<a href="#rid45">45,46</a>]. In the open-label extension of this study, fewer subjects receiving tocilizumab experienced a decline in FVC compared with those receiving placebo [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A phase 3 clinical trial (focuSSced) to assess the efficacy of <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> in SSc randomly assigned 210 patients to receive tocilizumab 162 mg or placebo by subcutaneous injection, weekly for 48 weeks [<a href="#rid48">48</a>]. Patients were not on immunomodulatory therapy at enrollment, but a stable dose of oral glucocorticoid was allowed. While there was no difference in the primary endpoint (ie, improvement in skin findings according to the mRSS) between the tocilizumab and placebo-treated groups, a benefit of tocilizumab on lung function was observed at 48 weeks. Among patients with evidence of ILD on baseline HRCT, the mean change in FVC from baseline at 48 weeks was -14 mL with tocilizumab and -255 mL with placebo (LSM difference 241 mL; 95% CI 124-358). A 48-week, open-label extension (181 of the original 212 participants) showed continued preservation of FVC in the continuous tocilizumab group, similar to that seen in the parent study [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Anticytokine therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2021550599"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span>We view <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> as a less optimal treatment alternative to MMF or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> for SSc-ILD due to the increased risk of adverse effects associated with cyclophosphamide [<a href="#rid28">28</a>]. When using cyclophosphamide for the treatment of SSc-ILD, we prefer intravenous dosing, given monthly for six months, rather than oral daily dosing for 12 months. In our experience, intravenous therapy allows for lower cumulative dose, less frequent adverse effects, and the ability to ensure adequate hydration prior to dosing (to reduce the risk of bladder toxicity). After completion of cyclophosphamide, patients commonly transition to a maintenance regimen with a less toxic agent (eg, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, tocilizumab, or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>). (See  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a> and <a class="local">'Maintenance therapy'</a> below.)</p><p>Evidence in support of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> for SSc-ILD is mixed. Randomized trials (described in the following sections) using both oral and intravenous routes of administration suggest that cyclophosphamide imparts modest benefit in SSc patients with early, symptomatic lung disease [<a href="#rid27">27,28,50,51</a>]. However, a meta-analysis of three randomized trials and six open label studies did not confirm an improvement in pulmonary function (ie, FVC and DLCO) with cyclophosphamide after 12 months [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H2797783804"><span class="h4">Intravenous cyclophosphamide</span><span class="headingEndMark"> — </span>While the two Scleroderma Lung Studies (SLS I and SLS II) used daily oral administration of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid27">27,28</a>], we prefer monthly intravenous administration, as noted above. The effectiveness of intravenous cyclophosphamide, used in combination with low dose glucocorticoid, at preventing deterioration of lung function in SSc-ILD has been studied in small observational studies and one randomized trial [<a href="#rid50">50,53-57</a>]. In the randomized trial, 45 patients were assigned to receive six monthly infusions of cyclophosphamide plus <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> (20 mg on alternate days) [<a href="#rid50">50</a>]. At 12 months, there was a modest improvement of FVC (4.19 percent) in the cyclophosphamide group compared with placebo after adjustment for baseline FVC, but this improvement did not achieve statistical significance. Neither DLCO nor measures of dyspnea showed improvement in either group. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Intermittent (pulse) cyclophosphamide'</a>.)</p><p class="headingAnchor" id="H9"><span class="h4">Oral cyclophosphamide</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> appears to be beneficial for some patients with symptomatic SSc-ILD [<a href="#rid27">27,58,59</a>], although not all studies have confirmed this finding as noted above [<a href="#rid52">52</a>]. Improvement in pulmonary function was demonstrated in a double-blind, multicenter trial (Scleroderma Lung Study I) that randomly assigned 158 patients with early SSc-ILD, dyspnea, an FVC between 45 and 85 percent of the predicted value, and evidence of active alveolar inflammation to receive either oral cyclophosphamide (≤2 mg/kg) or placebo daily for one year [<a href="#rid27">27</a>]. Evidence of active alveolar inflammation included ground-glass opacities on high resolution computed tomography or elevated numbers of neutrophils or eosinophils in bronchoalveolar lavage fluid. Concomitant glucocorticoids were permitted in doses equivalent to ≤10 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. Outcomes at 12 months were:</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> group had a smaller decline than the placebo group in FVC (-1 versus -2.6 percent of predicted) and total lung capacity (-0.3 versus -2.8 percent of predicted). DLCO was unchanged in both groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The percentage of patients with cough decreased in the <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> group from 71 percent at baseline to 56 percent, whereas the percentage of patients with cough in the placebo group remained the same (68 percent) at both baseline and 12 months [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> group had less progression of radiographic fibrosis compared to the placebo group [<a href="#rid61">61</a>]. No differences between the groups were noted regarding changes in ground glass opacities or honeycomb cysts. Subsequent analysis found that more severe fibrosis on HRCT was an independent predictor of a response to cyclophosphamide (improvement in forced vital capacity at 18 months) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More severe SSc based on measures of skin thickness, dyspnea severity, self-reported disability, and health related quality of life also favored <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid62">62</a>].</p><p></p><p>A follow-up study reported 24 month outcomes for 93 patients who completed one year of oral <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or placebo plus 52 who completed at least six months of cyclophosphamide or placebo and returned at 24 months or had their 24-month data imputed [<a href="#rid63">63</a>]. Of the 48 patients who had received cyclophosphamide, 12 also received low dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. The beneficial effects of cyclophosphamide on FVC appeared to persist for six months after stopping the drug. However, by 24 months the improvement in FVC was no longer present, suggesting that the pulmonary response to cyclophosphamide is not durable. </p><p>In SLS II, oral <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> was initiated at 50 to 150 mg/day (based on weight) and increased gradually over three months to a maximum dose of 1.8 to 2.3 mg/kg [<a href="#rid28">28</a>]. Details of oral cyclophosphamide dosing are provided separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Daily oral cyclophosphamide'</a>.)</p><p class="headingAnchor" id="H1564984772"><span class="h4">Monitoring and adverse effects</span><span class="headingEndMark"> — </span>White blood cell count, renal function, and urinalysis should be monitored monthly during <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> therapy. A detailed discussion about monitoring and parameters for withholding cyclophosphamide is provided separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Monitoring of oral CYC dosing'</a>.)</p><p><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> has short and long-term potential toxicities, including infertility, opportunistic infections, hemorrhagic cystitis, bladder cancer, neutropenia, and adverse drug interactions [<a href="#rid64">64</a>]. Patients should use effective contraception to prevent pregnancy during cyclophosphamide therapy. (See  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases", section on 'Toxicity'</a>.)</p><p>Immunosuppressed patients are at increased risk for <em>Pneumocystis jirovecii</em> pneumonia (PCP, previously called <em>Pneumocystis carinii</em>); thus, we suggest that patients taking <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> also receive prophylaxis against PCP, which is described separately. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Adjuvant glucocorticoids</span><span class="headingEndMark"> — </span>The role of adjuvant low dose of oral glucocorticoids (equivalent of ≤10 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) in combination with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is unclear. In studies evaluating the efficacy of cyclophosphamide versus placebo in SSc-ILD, many patients also received low dose glucocorticoid [<a href="#rid27">27,50</a>]. However, evidence in support of this practice is lacking, and we reserve low dose glucocorticoids for patients with other indications for glucocorticoids (eg, arthritis, pruritus).</p><p>We avoid combining high dose glucocorticoids with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> because of the lack of clinical trial data and the attendant risks of scleroderma renal crisis and opportunistic infection.</p><p class="headingAnchor" id="H5326294"><span class="h3">Azathioprine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> appears less efficacious as initial therapy for SSc-ILD than <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and by extension MMF, although it has not been directly compared with MMF [<a href="#rid65">65</a>]. In an unblinded trial, 60 patients with early diffuse SSc and ILD were randomly assigned to receive either cyclophosphamide (up to 2 mg/kg per day) or azathioprine (2.5 mg/kg per day up to a maximum of 150 mg/day). During the first six months of therapy, patients in both groups also received <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> (15 mg/day), which was subsequently tapered. After 18 months, FVC and diffusion capacity were stable in patients treated with cyclophosphamide but had declined in patients treated with azathioprine. Leukopenia was more frequent in the cyclophosphamide group. Azathioprine has not been directly compared with <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>.</p><p>A retrospective analysis of eight patients with SSc-ILD who received <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> for worsening pulmonary symptoms or declining lung function for a minimum of 12 months showed that five patients had &gt;10 percent improvement of FVC and three patients remained stable [<a href="#rid66">66</a>]. Three other patients discontinued azathioprine due to adverse effects within the first six months of therapy.</p><p><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> dosing and monitoring for adverse effects are discussed separately, along with pretreatment testing for thiopurine S-methyltransferase (TPMT) deficiency. TPMT deficiency confers increased risk of life-threatening immunosuppression with azathioprine therapy. Typically, a complete blood count and liver function tests are obtained monthly for the first few months of therapy, and then every three months once a stable dose is achieved. The dosing of azathioprine, including potential testing for thiopurine S-methyltransferase (TPMT) deficiency, and monitoring for adverse effects are described separately. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Pharmacogenetics and azathioprine toxicity'</a>.)</p><p class="headingAnchor" id="H23254633"><span class="h1">MAINTENANCE THERAPY</span><span class="headingEndMark"> — </span>After a course of initial therapy, immunomodulatory therapy is usually continued for months to years. Neither the optimal choice of agent for maintenance therapy nor the treatment duration is known.</p><p>Part of the rationale for long-term therapy is that the improvements in lung function associated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> appear to wane in the 12 months after discontinuation of active therapy [<a href="#rid63">63</a>] (see <a class="local">'Oral cyclophosphamide'</a> above). While both CYC and MMF have been shown to improve pulmonary function up to 24 months, long-term survival was similar in the CYC and placebo groups of SLS I and also in the MMF and CYC groups of SLS II [<a href="#rid20">20,28</a>].</p><p>Observational data and clinical experience support the use of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (eg, 1.5 to 3 g daily, usually in two divided doses) or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> as maintenance agents [<a href="#rid57">57,67</a>]. In our practice, we generally select MMF over azathioprine due to the evidence of efficacy seen in the Scleroderma Lung Study II (SLS II) [<a href="#rid28">28</a>], unless the patient has previously not tolerated MMF.</p><p><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> is an alternative to MMF for maintenance therapy, based on long-term use in rheumatoid arthritis, although its long-term use in SSc-ILD has not been formally studied. Maintenance with this agent is reasonable in patients who experience initial benefit with tocilizumab and do not have any adverse effects. (See <a class="local">'Tocilizumab'</a> above.)</p><p>Maintenance therapy is typically continued until the patient has experienced a long period of stability (at least 12 to 24 months) in respiratory symptoms and function or develops progressive disease (prompting consideration of an alternative agent). However, the optimal duration of immunosuppressive treatment is unknown. During maintenance therapy, adjuvant glucocorticoids are usually reserved for patients who have an extrapulmonary indication for them, such as arthritis or pruritus. (See <a class="local">'Mycophenolate mofetil'</a> above and <a class="local">'Monitoring response to therapy'</a> below and  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Mycophenolate dose and administration'</a>.)</p><p class="headingAnchor" id="H2021548597"><span class="h1">PROGRESSIVE DISEASE</span></p><p class="headingAnchor" id="H1425155790"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Several agents have been used for SSc patients who experience progressive loss of lung function despite treatment with the above drugs. Prior to pursuing other therapies for SSc-ILD, these patients should be reassessed for potential reasons for lack of clinical improvement, such as other disease complications (eg, aspiration pneumonitis, pleural or pericardial disease, pulmonary hypertension) or comorbid disease (eg, thromboembolic disease and chronic obstructive pulmonary disease [COPD]).</p><p>For patients whose disease is refractory to immunomodulatory agents, we suggest addition of <a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">nintedanib</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to ongoing therapy (eg, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>). Patients with more inflammatory features on imaging may benefit more from rituximab, while those with more fibrosis features may benefit more from nintedanib. In practice, the combination of mycophenolate and nintedanib is often poorly tolerated (typically due to diarrhea), and dose reductions are frequently employed.</p><p>Patients with progressive disease and without contraindications should undergo evaluation for lung transplantation.</p><p>Patients who are candidates for clinical trials may wish to pursue this option and can be referred to (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4375" target="_blank">ClinicalTrials.gov</a>).</p><p class="headingAnchor" id="H4206875184"><span class="h2">Nintedanib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">Nintedanib</a>, an inhibitor of multiple tyrosine kinases, slows disease progression in idiopathic pulmonary fibrosis (IPF) and is approved by the US FDA for use in IPF [<a href="#rid68">68</a>] (see  <a class="medical medical_review" href="/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'</a>), progressive fibrosing ILD [<a href="#rid69">69</a>], and SSc-ILD [<a href="#rid70">70,71</a>]. Randomized trials have demonstrated benefit with nintedanib in the treatment of SSc-ILD, with a reduced rate of loss of forced vital capacity (FVC) [<a href="#rid71">71,72</a>]. Based on these results, nintedanib may be used to slow the progression of SSc-ILD; however, the patients with SSc-ILD most likely to benefit from nintedanib, and the optimal timing of initiation and duration of treatment, remain unknown. It is our opinion that patients with SSc-ILD who demonstrate disease progression despite MMF or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, especially in the first one to two years of treatment given the association with increased mortality [<a href="#rid20">20</a>], may benefit from the addition of nintedanib to standard therapy [<a href="#rid71">71</a>]. Nintedanib may also be an alternative treatment for SSc-ILD in patients who are unable to take MMF or cyclophosphamide. However, whether it is appropriate to initiate treatment of SSc-ILD with nintedanib as monotherapy has not been determined.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The dose of <a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">nintedanib</a> is 150 mg twice daily, approximately 12 hours apart. Liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin) should be assessed prior to initiation of nintedanib; patients with moderate or severe hepatic impairment (Child Pugh B or C) should not take nintedanib [<a href="#rid70">70</a>]. Importantly, nintedanib can cause fetal harm. Thus, a pregnancy test should be performed prior to initiation of nintedanib in women of reproductive potential, and highly effective contraception should be used during therapy [<a href="#rid70">70</a>]. While nintedanib does not impair the effectiveness of oral contraceptives, diarrhea and/or vomiting can compromise absorption, which may necessitate use of an alternate contraceptive method. Conception should be avoided until at least three months after the last dose of nintedanib. The dosing and administration of nintedanib are discussed separately. (See  <a class="medical medical_review" href="/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Dose and administration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In the SENSCIS trial, 576 subjects with SSc-ILD were randomly assigned to <a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">nintedanib</a> 150 mg or placebo twice daily for 52 weeks; approximately half of the patients in each arm of the study were taking <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (MMF) at baseline [<a href="#rid71">71</a>]. The adjusted annual rate of change in FVC was -52.4 mL/year in the nintedanib-treated group and -93.3 mL/year in the placebo-treated group (difference of 41 mL/year, 95% CI 2.9-79), demonstrating benefit with use of nintedanib. The relative reduction in rate of annual FVC decline was comparable to that seen in the trials of nintedanib in IPF (44 percent versus 49 percent) [<a href="#rid68">68</a>]. A difference in the degree of change in FVC was also observed when comparing patients receiving MMF combined with nintedanib versus MMF alone, although this difference was smaller (-40.2 mL/year and -66.5 mL/year). No significant difference was noted in the mRSS, respiratory symptoms, or health-related quality of life between placebo and nintedanib-treated groups. Diarrhea was the most common adverse effect, reported in 76 percent of patients treated with nintedanib, and was also the most frequent side effect in the prior nintedanib trials in IPF [<a href="#rid68">68</a>]. For those that developed diarrhea, 51.8 percent had the onset of diarrhea within the first 30 days of treatment [<a href="#rid73">73</a>]. A reduced rate of FVC decline was also seen in SSc-ILD patients in the INBUILD trial (-45.4 mL/year versus -166.1 mL/year), although SSc-ILD patients made up a very small portion of that trial population and this difference in FVC decline was not statistically significant [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H2021550311"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is a monoclonal antibody that targets CD20-positive B lymphocytes, leading to prolonged depletion of circulating B cells in most patients. Based on promising results from small clinical trials and some observational studies, rituximab may be an option for SSc-ILD [<a href="#rid74">74-77</a>]. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p>The potential efficacy of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for SSc-ILD was examined in a trial that compared rituximab with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> therapy in 101 patients with various forms of connective tissue disease-associated ILD (40 percent with scleroderma) [<a href="#rid78">78</a>]. Rituximab showed similar efficacy to cyclophosphamide, with both treatments resulting in improvements in FVC at 24 and 48 weeks, six-minute walk distance at 24 weeks, and quality of life at 24 and 48 weeks compared with baseline.</p><p>Longer-term outcomes of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> were assessed in a much smaller trial of SSc-ILD patients that compared efficacy of rituximab plus "standard therapy" (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and/or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) with standard therapy alone [<a href="#rid74">74</a>]. The eight patients in the rituximab group had significantly better forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) at one year than the six patients receiving standard therapy alone [<a href="#rid74">74</a>]. In a follow-up study, the eight patients in the rituximab arm received two additional cycles of rituximab a 12 and 18 months and were reassessed at two years [<a href="#rid79">79</a>]. A significant increase in FVC compared with baseline was noted (median percentage improvement 12.79). DLCO also increased relative to baseline (mean ± SEM: 63.13 ± 7.65 versus 52.25 ± 7.32, respectively, p &lt;0.001).</p><p>Although one case series did not observe a benefit to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> treatment for SSc-ILD [<a href="#rid80">80</a>], most observational studies have shown stabilization or improvement in lung function following rituximab initiation [<a href="#rid80">80-83</a>]. In a systematic review including two trials and several observational studies of patients with SSc-ILD (575 participants), rituximab resulted in a modest 4.5 percent (95% CI 0.25-8.7) improvement in FVC at six months and a 7.0 percent (95% CI 4.4-9.7) improvement in FVC at 12 months [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H23254810"><span class="h2">Lung transplantation</span><span class="headingEndMark"> — </span>Lung transplantation may be an option for carefully selected SSc patients with severe ILD that is not responsive to pharmacologic interventions [<a href="#rid84">84,85</a>]. However, careful evaluation for extrapulmonary SSc-related disease (eg, uncontrolled aspiration due to esophageal disease, renal or cardiac disease) that might impair tolerance of lung transplantation is essential. While esophageal dysmotility and gastroesophageal reflux require careful evaluation, they need not be a contraindication to transplantation when they are well-controlled [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a>.)</p><p>SSc patients undergoing lung transplantation appear to have morbidity and mortality comparable to patients without SSc undergoing lung transplantation for fibrotic lung disease [<a href="#rid87">87-94</a>], although results vary among studies.</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective, single center study, the outcomes of 72 consecutive patients with SSc-ILD who underwent lung transplantation were compared with those of 311 patients with advanced fibrotic lung disease due to idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, or rheumatic diseases other than SSc [<a href="#rid91">91</a>]. Post-transplant survival did not differ at one year or at five years (conditional on one year survival). Pretransplant, esophageal function was assessed by cine esophagram, but only a limited number of patients underwent impedance studies or 24-hour pH probe monitoring. Among 248 patients with SSc-ILD who were referred for consideration for transplant, 146 were evaluated, 89 were listed, and 72 underwent transplantation. The details of reasons that patients were not evaluated or not listed for transplant were not provided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 90 patients with SSc-ILD who underwent transplantation between 1993 and 2016 at 14 European centers, survival rates at 1, 3, and 5 years were 81, 68, and 61 percent, respectively [<a href="#rid95">95</a>]. The combination of female sex and pulmonary arterial hypertension was associated with poorer survival.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single center study, lung transplant outcomes were compared among patients with SSc-ILD (n = 35), non-SSc fibrotic lung disease (n = 264), and a non-SSc matched group (n = 109) [<a href="#rid90">90</a>]; 91 percent of the SSc patients received a bilateral lung transplant. The one-, three-, and five-year survivals for SSc-ILD (94, 77, and 70 percent, respectively) were similar to the non-SSc fibrotic lung disease and matched groups. Although 60 percent of the SSc patients had severe esophageal dysfunction, this comorbidity did not appear to adversely affect transplant outcomes. The transplant center used multidisciplinary assessments to determine whether reflux was symptomatically quiescent or nearly so prior to accepting patients for transplant. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study used the United Network for Organ Sharing database to examine the outcome of 229 adults with SSc-ILD who underwent lung transplantation in the United States [<a href="#rid84">84</a>]. The one-year survival of SSc patients was significantly worse compared to patients with IPF, but comparable to that of patients with idiopathic pulmonary arterial hypertension (PAH) unrelated to systemic sclerosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review that predated the above studies found that the short-term and intermediate-term post-lung transplantation survival was similar in patients with SSc-ILD, PAH, and other forms of ILD [<a href="#rid96">96</a>].</p><p></p><p class="headingAnchor" id="H20"><span class="h1">MONITORING RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>The optimal tools and timing for assessing treatment response in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) are unknown. Our approach is to evaluate patients initially at least monthly for adverse effects of therapy. In the absence of drug-related adverse effects, we assess respiratory symptoms, subjective exercise tolerance, physical exam, and pulmonary function tests (eg, spirometry, diffusing capacity for carbon monoxide [DLCO], six-minute walk test) at approximately three-month intervals [<a href="#rid97">97,98</a>]. Chest high resolution computed tomography (HRCT) is rarely repeated for monitoring purposes, as there are no data to support the use of serial HRCT in this setting. We generally obtain a follow-up HRCT only in response to a change in symptoms or pulmonary function tests, or when there is concern about lung infection or lung cancer [<a href="#rid99">99</a>]. </p><p>Assessing the respiratory response to therapy is challenging because:</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement tends to occur slowly</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small changes in symptoms, lung function, and/or radiographic appearance can be masked by the effect of existing fibrosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stabilization in lung function, rather than improvement, may be the best result that can be expected</p><p></p><p>Quantitative HRCT, a research tool that uses computer modelling to quantify the extent of reticulation, ground glass, and honeycomb patterns, appears to be a sensitive indicator of disease progression and response to treatment [<a href="#rid86">86,100</a>]. Further study is needed to determine if it has a role in routine monitoring.</p><p>It is important to remember that worsening respiratory symptoms or pulmonary function tests in SSc may reflect development of a different disease complication, such as pulmonary hypertension, aspiration, or pleural effusion. The clinical presentation and evaluation of other pulmonary complications of SSc are discussed separately. (See  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>Patients with SSc-ILD should receive the same supportive therapies used for the management of other types of ILD. These measures include cigarette smoking cessation, supplemental oxygen as indicated by pulse oxygen saturation, yearly influenza vaccination, SARS-CoV-2 (COVID-19) vaccination, and age-appropriate pneumococcal vaccination (PPS23 and <a class="drug drug_general" data-topicid="9906" href="/d/drug information/9906.html" rel="external">PCV13</a>). While not specifically studied in SSc-ILD, pulmonary rehabilitation may also be of benefit in reducing dyspnea and improving exercise tolerance. (See  <a class="medical medical_review" href="/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a> and  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a>.)</p><p class="headingAnchor" id="H1858228663"><span class="h2">Gastroesophageal reflux and aspiration</span><span class="headingEndMark"> — </span>Gastrointestinal manifestations of scleroderma are common and include gastrointestinal reflux disease (GERD) and esophageal dysmotility. It is our practice to treat GERD aggressively in SSc-ILD, especially for those with evidence or symptoms of such, and to advise lifestyle modifications (eg, head of bed elevation to 30 degrees, avoidance of meals and alcohol two hours prior to bedtime) for those for whom microaspiration is suspected based on symptoms, presence of a patulous esophagus, or CT findings suggesting aspiration. (See  <a class="medical medical_review" href="/d/html/7548.html" rel="external">"Gastrointestinal manifestations of systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/d/html/7556.html" rel="external">"Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)"</a>.)</p><p>In a study of 40 patients with SSc who underwent 24 hours of esophageal pH monitoring, those with SSc-ILD had a higher amount of acid exposure and a greater number of reflux episodes than those without ILD [<a href="#rid101">101</a>]. In a study of 270 SSc patients, increasing diameter of the esophagus was associated with ILD severity and decreased pulmonary function [<a href="#rid102">102</a>]. Further research is needed to understand the interaction between GERD and microaspiration and the development and progression of SSc-ILD. </p><p class="headingAnchor" id="H25"><span class="h1">INVESTIGATIONAL APPROACHES</span><span class="headingEndMark"> — </span>Several potential therapies for SSc-ILD are under investigation. These include <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>, intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), and hematopoietic cell transplantation. Additionally, agents that have efficacy in the treatment of idiopathic pulmonary fibrosis (IPF), such as <a class="drug drug_general" data-topicid="88424" href="/d/drug information/88424.html" rel="external">pirfenidone</a>, are undergoing evaluation in SSc-ILD.</p><p>Information about clinical trials for patients with SSc-associated lung disease is available at: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4375" target="_blank">clinicaltrials.gov</a></p><p class="headingAnchor" id="H685018260"><span class="h2">Pirfenidone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="88424" href="/d/drug information/88424.html" rel="external">Pirfenidone</a> is an antifibrotic agent that is approved for use in idiopathic pulmonary fibrosis, although the precise mechanism of action is not known. In a case series of five patients with SSc-ILD, administration of pirfenidone (1200 to 1800 mg/day) was associated with a reduction in dyspnea and an increase in vital capacity; in four patients, the vital capacity had decreased approximately 10 percent prior to initiation of pirfenidone [<a href="#rid103">103</a>]. The safety and tolerability of pirfenidone in SSc-ILD was evaluated in the LOTUSS study, which was an open-label study of escalating doses of pirfenidone up to 2403 mg/day (the approved dose in IPF) in 63 patients with SSc-ILD [<a href="#rid104">104,105</a>]. Pirfenidone was generally well-tolerated in this group of SSc patients, despite underlying gastrointestinal disease and concomitant use of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil. The most common treatment emergent adverse events (&gt;10 percent of patients) were nausea, headache, fatigue, and vomiting, consistent with those previously seen with pirfenidone in IPF. A larger clinical trial to investigate the efficacy of pirfenidone has been initiated.</p><p class="headingAnchor" id="H2273433440"><span class="h2">Abatacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> inhibits T-cell (T-lymphocyte) activation by binding to CD80 and CD86 on antigen presenting cells (APCs), thus blocking the required CD28 interaction between APCs and T cells. In a report of two patients with SSc-ILD, both experienced improvements in diffusing capacity for carbon monoxide (DLCO), FVC, and TLC; and one had marked regression of ILD changes on HRCT [<a href="#rid106">106</a>]. However, in an observational study that included six patients with ILD, no improvement in lung function was noted after five months of abatacept 10 mg/kg/month. However, the HRCT was described as showing fibrotic changes and the lung function outcomes were not a main focus of the study. A randomized Phase 2 trial of subcutaneous abatacept in patients with SSc showed no benefit of abatacept on FVC [<a href="#rid107">107</a>]. </p><p class="headingAnchor" id="H1837024688"><span class="h2">Hematopoietic stem cell transplantation</span><span class="headingEndMark"> — </span>Immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HSCT) has shown benefit in some patients with severe diffuse cutaneous SSc [<a href="#rid108">108-110</a>]. Given the mortality and morbidity associated with hematopoietic cell transplantation, these procedures are best performed in specialized centers with significant expertise in the procedure. Autologous HSCT for patients with SSc is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Autologous stem cell transplantation'</a>.)</p><p class="headingAnchor" id="H2021549528"><span class="h1">AGENTS UNLIKELY TO BE OF BENEFIT</span><span class="headingEndMark"> — </span>Many drugs that were previously used for SSc-ILD produced no improvement in lung function. Ineffective drugs include <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, para-aminobenzoic acid, <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>, disodium ethylenediaminetetraacetic acid (EDTA), methysergide, and relaxin [<a href="#rid111">111-114</a>]. Additional agents without clear benefit include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9747" href="/d/drug information/9747.html" rel="external">D-Penicillamine</a> – D-Penicillamine is an immunomodulatory agent that inhibits the formation of collagen crosslinks. While it has been used for over four decades to treat SSc, the efficacy of D-penicillamine in SSc remains uncertain, and side effects are common and may be serious. Several retrospective studies demonstrated clinical benefits, including an improved skin score, less new organ involvement, and improved survival [<a href="#rid115">115-117</a>]. However, in a trial that randomly assigned 134 patients with diffuse SSc to receive either standard dose (750 to 1000 mg/day) or low dose (125 mg every other day) D-penicillamine, there was no difference in the extent of skin involvement or survival [<a href="#rid118">118</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – Glucocorticoids, either as monotherapy or in combination with other drugs, have been widely used to treat SSc-ILD with variable benefit [<a href="#rid111">111,119-125</a>]. Given the lack of convincing benefit and the increased risk for scleroderma renal crisis, glucocorticoid monotherapy is not recommended (see  <a class="medical medical_review" href="/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Risk factors'</a>). However, low dose glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> ≤10 mg/day) are sometimes administered in combination with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. (See <a class="local">'Adjuvant glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong> – <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> has been used to treat both SSc and localized forms of scleroderma with modest improvement in skin involvement; however, a beneficial effect on lung involvement has not been demonstrated. Because methotrexate has been occasionally associated with the development of pneumonitis, we do not recommend its use in the treatment of SSc-ILD. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor necrosis factor-alpha antagonists</strong> – Antagonists of tumor necrosis factor (TNF)-alpha have not been beneficial in systemic sclerosis. (See  <a class="medical medical_review" href="/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Anticytokine therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2021548450"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In patients with systemic sclerosis (SSc), interstitial lung disease (ILD) predicts increased mortality [<a href="#rid2">2,3,6,8,13</a>]. This was illustrated by a retrospective study of 953 patients with SSc; patients with severe ILD had a nine-year survival rate of approximately 30 percent, whereas patients with SSc who did not have severe involvement of an organ system had a nine-year survival rate of 72 percent [<a href="#rid13">13</a>]. </p><p>A variety of parameters have been examined as predictors of outcome in SSc-ILD:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of 1616 patients with SSc-ILD, older age, lower forced vital capacity (FVC), and lower diffusing capacity for carbon monoxide (DLCO) predicted mortality in more than one study [<a href="#rid126">126</a>]. In a separate retrospective analysis of two randomized trials, a decline in FVC and DLCO over two years was a better predictor of mortality than baseline FVC or DLCO [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a database study of 826 patients with SSc-ILD, 219 (27 percent) had a moderate (5 to 10 percent) or significant (&gt;10 percent) decline in lung function over 12 ± 3 months of monitoring [<a href="#rid127">127</a>]. A pattern of slow FVC decline was most common (58 percent), while a rapid, continuous decline in FVC was noted in 8 percent, and stable lung function in 33 percent. Male sex, higher modified Rodnan skin score, and reflux or dysphagia symptoms were the strongest predictors for FVC decline over five years. Male patients have also demonstrated higher rates of FVC decline and increased mortality in randomized trials [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The extent of disease on high resolution computed tomography (HRCT) independently predicted mortality and ILD progression in the systematic review [<a href="#rid126">126</a>]. Furthermore, the presence of combined pulmonary fibrosis and emphysema (CPFE) carries a higher morbidity and mortality in SSc patients than SSc-ILD without coexistent emphysema [<a href="#rid129">129</a>]. In a retrospective case-control series, CPFE SSc patients were more like to have pulmonary hypertension and worse survival compared with SSc-ILD alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The symptomatic and physiologic severity of SSc-ILD are better predictors of outcome than histopathologic subtype. In a retrospective histopathological evaluation of 80 patients with SSc and biopsy proven ILD, 76 percent had nonspecific interstitial pneumonia (NSIP) and 11 percent had usual interstitial pneumonia (UIP) [<a href="#rid8">8</a>]. The five-year survival rate for patients with NSIP and UIP was similar, 82 and 91 percent, respectively. Markers of a worse prognosis included a lower diffusion capacity (DLCO) and a more rapid decline of DLCO over three years. </p><p></p><p>Bronchoalveolar lavage (BAL) cell counts, once thought to have prognostic value, do not appear to be a reliable indicator of prognosis [<a href="#rid8">8,24-26</a>]. Although one retrospective study reported that increased eosinophils in the BAL fluid was associated with a poorer prognosis, a larger prospective cohort study of 141 patients with SSc-ILD found that the proportion of eosinophils in the BAL fluid did not correlate with mortality, rate of functional deterioration, or progression-free survival [<a href="#rid8">8,24</a>]. An increased proportion of neutrophils in BAL fluid was associated with more extensive lung disease on HRCT, a greater reduction in DLCO, and early mortality (HR 8.40, 95% CI 1.91-36.95), but it did not predict the rate of functional deterioration or progression-free survival [<a href="#rid24">24</a>]. In a prospective clinical trial of 158 patients with early-stage SSc and symptomatic lung involvement, the presence or absence of BAL fluid neutrophilia did not predict rate of worsening or response to therapy [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H3131882981"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118282.html" rel="external">"Society guideline links: Systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for therapy</strong> – Significant interstitial lung disease (ILD) predicts poor outcome in patients with systemic sclerosis (SSc). The decision to initiate ILD-directed therapy must be made on a case-by-case basis after carefully balancing the potential benefits of treatment and the toxicities of therapy. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing extent and severity of ILD</strong> – When deciding whether to initiate treatment for SSc-ILD, the extent and severity of ILD are assessed by a combination of clinical findings (eg, degree of dyspnea), high resolution computed tomography (HRCT), and pulmonary function testing. These tests are used to estimate the extent of disease and likelihood of progression  (<a class="graphic graphic_table graphicRef105688" href="/d/graphic/105688.html" rel="external">table 1</a>). Worsening pulmonary function demonstrated by serial testing (eg, a decrease in forced vital capacity or diffusing capacity for carbon monoxide ≥10 percent) may be the most reliable indicator of progressive lung impairment. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – For patients with SSc-ILD who have respiratory symptoms, abnormal and/or declining pulmonary function, imaging evidence of ILD, and no evidence of active infection, we suggest <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) as initial therapy rather than other options (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), based on the relatively good side effect profile and length of clinical experience with this agent; however, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> are reasonable alternatives in selected patients. (See <a class="local">'Choice of initial agent'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mycophenolate</strong> – MMF is administered orally in gradually increasing doses to enhance gastrointestinal tolerance, with a target dose of 1.5 to 3 g/day in two divided doses. Dosing of antacids and mineral supplements should be separated from MMF by least two hours. Routine monitoring for bone marrow suppression is required. (See <a class="local">'Mycophenolate mofetil'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tocilizumab</strong> – <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> (162 mg weekly by subcutaneous injection) is an alternative for initial therapy in patients with early-stage SSc-ILD who are not able to take MMF, have elevated levels of acute phase markers, or have other indications for anti-IL6 therapy. While the clinical experience with tocilizumab is less than with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, tocilizumab has a better safety profile than cyclophosphamide and can be used for both initial and long-term therapy. (See <a class="local">'Tocilizumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cyclophosphamide</strong> – <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> is administered via monthly intravenous infusions for six months, or via daily oral dosing for 12 months. We prefer monthly intravenous treatments due to the lower cumulative dose, less frequent adverse effects (in our experience), and the ability to ensure adequate hydration prior to dosing. Careful monitoring for adverse effects and drug interactions is essential. (See <a class="local">'Cyclophosphamide'</a> above and  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The duration of MMF is not well-established. Typically, maintenance treatment is continued for at least 24 months and often for several years, depending on the patient’s course. (See <a class="local">'Dose and duration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The approach to maintenance therapy in patients treated with an alternative initial agent is discussed above. (See <a class="local">'Maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive disease</strong> – For patients whose disease is refractory to the above measures, we suggest addition of <a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">nintedanib</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to ongoing therapy (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with more fibrosis on lung imaging findings may benefit more from nintedanib, while those with more inflammatory features may benefit more from rituximab. Lung transplantation evaluation should be offered in patients with progressive disease who have no contraindications. Some patients with SSc-ILD may prefer to explore experimental treatment modalities (eg, hematopoietic stem cell transplantation, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>, or <a class="drug drug_general" data-topicid="88424" href="/d/drug information/88424.html" rel="external">pirfenidone</a>); information about clinical trials is available at: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4375" target="_blank">Clinicaltrials.gov</a>. (See <a class="local">'Progressive disease'</a> above and <a class="local">'Investigational approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Changes in the patient's symptoms, subjective exercise tolerance, and pulmonary function are monitored at approximately three- to six-month intervals. Serial HRCTs are not obtained routinely, only when clinically indicated. For patients whose disease stabilizes or improves, maintenance therapy is continued until the improvement reaches a plateau at which time gradual withdrawal of therapy can be considered. (See <a class="local">'Monitoring response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of pregnancy</strong> – Every effort should be made to avoid pregnancy during therapy with MMF, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, or <a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">nintedanib</a>. Information about other rheumatic disease medications is provided separately. (See <a class="local">'Monitoring and adverse effects'</a> above and <a class="local">'Monitoring and adverse effects'</a> above and  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Pneumocystis </em></strong><strong>prophylaxis</strong> – We advise giving prophylaxis to prevent <em>Pneumocystis jirovecii</em> (previously called <em>Pneumocystis carinii</em>) pneumonia for patients receiving <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> as described separately. Such prophylaxis is less clearly needed and less routinely given, for patients receiving MMF or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> alone. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a> and  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Pneumocystis jirovecii'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung transplantation</strong> – Selected SSc patients who have severe ILD that is unresponsive to therapy may be referred for lung transplantation. (See <a class="local">'Lung transplantation'</a> above and  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a>.)</p><p></p><p class="headingAnchor" id="H2058268860"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Andrew M Tager, MD, now deceased, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014; 66:1967.</a></li><li><a class="nounderline abstract_t">Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269.</a></li><li><a class="nounderline abstract_t">Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60:569.</a></li><li><a class="nounderline abstract_t">Suliman YA, Dobrota R, Huscher D, et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheumatol 2015; 67:3256.</a></li><li><a class="nounderline abstract_t">Steele R, Hudson M, Lo E, et al. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64:519.</a></li><li><a class="nounderline abstract_t">Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005; 17:737.</a></li><li><a class="nounderline abstract_t">Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940.</a></li><li><a class="nounderline abstract_t">Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581.</a></li><li><a class="nounderline abstract_t">Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175:705.</a></li><li><a class="nounderline abstract_t">Belloli EA, Beckford R, Hadley R, Flaherty KR. Idiopathic non-specific interstitial pneumonia. Respirology 2016; 21:259.</a></li><li><a class="nounderline abstract_t">Walsh SL, Sverzellati N, Devaraj A, et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014; 69:216.</a></li><li><a class="nounderline abstract_t">Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol 2014; 10:728.</a></li><li><a class="nounderline abstract_t">Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437.</a></li><li><a class="nounderline abstract_t">Iudici M, Moroncini G, Cipriani P, et al. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmun Rev 2015; 14:575.</a></li><li><a class="nounderline abstract_t">Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52:155.</a></li><li><a class="nounderline abstract_t">Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66:1625.</a></li><li><a class="nounderline abstract_t">Steen VD, Lanz JK Jr, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37:1290.</a></li><li><a class="nounderline abstract_t">Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63:3078.</a></li><li><a class="nounderline abstract_t">Showalter K, Hoffmann A, Rouleau G, et al. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. J Rheumatol 2018; 45:1572.</a></li><li><a class="nounderline abstract_t">Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis 2019; 78:122.</a></li><li><a class="nounderline abstract_t">Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. Am J Respir Crit Care Med 2019; 200:1258.</a></li><li><a class="nounderline abstract_t">Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248.</a></li><li><a class="nounderline abstract_t">Morisset J, Vittinghoff E, Elicker BM, et al. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest 2017; 152:999.</a></li><li><a class="nounderline abstract_t">Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56:2005.</a></li><li><a class="nounderline abstract_t">Harrison NK, Glanville AR, Strickland B, et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989; 83:403.</a></li><li><a class="nounderline abstract_t">Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177:91.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4:708.</a></li><li><a class="nounderline abstract_t">Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40:84.</a></li><li><a class="nounderline abstract_t">Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45:1005.</a></li><li><a class="nounderline abstract_t">Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130:30.</a></li><li><a class="nounderline abstract_t">Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011; 30:1393.</a></li><li><a class="nounderline abstract_t">Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337:329.</a></li><li><a class="nounderline abstract_t">Koutroumpas A, Ziogas A, Alexiou I, et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29:1167.</a></li><li><a class="nounderline abstract_t">Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39:1241.</a></li><li><a class="nounderline abstract_t">Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102:150.</a></li><li><a class="nounderline abstract_t">Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008; 133:455.</a></li><li><a class="nounderline abstract_t">Yilmaz N, Can M, Kocakaya D, et al. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. Int J Rheum Dis 2014; 17:923.</a></li><li><a class="nounderline abstract_t">Owen C, Ngian GS, Elford K, et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol 2016; 34 Suppl 100:170.</a></li><li><a class="nounderline abstract_t">Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol 2017; 69:1451.</a></li><li><a class="nounderline abstract_t">Naidu GSRSNK, Sharma SK, Adarsh MB, et al. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial. Rheumatol Int 2020; 40:207.</a></li><li><a class="nounderline abstract_t">Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004; 1:165.</a></li><li><a class="nounderline abstract_t">De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40:435.</a></li><li class="breakAll">FDA prescribing information for tocilizumab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125472s044lbl.pdf.</li><li><a class="nounderline abstract_t">Denton C, Khanna D, van Laar JM, et al. Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial. Rheumatology (Oxford) 2015; 54:i32.</a></li><li><a class="nounderline abstract_t">Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387:2630.</a></li><li><a class="nounderline abstract_t">Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018; 77:212.</a></li><li><a class="nounderline abstract_t">Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020; 8:963.</a></li><li><a class="nounderline abstract_t">Khanna D, Lin CJF, Furst DE, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med 2022; 205:674.</a></li><li><a class="nounderline abstract_t">Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962.</a></li><li><a class="nounderline abstract_t">Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63:2797.</a></li><li><a class="nounderline abstract_t">Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10:R124.</a></li><li><a class="nounderline abstract_t">Várai G, Earle L, Jimenez SA, et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25:1325.</a></li><li><a class="nounderline abstract_t">Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29:731.</a></li><li><a class="nounderline abstract_t">Airò P, Danieli E, Parrinello G, et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22:573.</a></li><li><a class="nounderline abstract_t">Tzelepis GE, Plastiras SC, Karadimitrakis SP, Vlachoyiannopoulos PG. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease. Clin Exp Rheumatol 2007; 25:734.</a></li><li><a class="nounderline abstract_t">Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35:1064.</a></li><li><a class="nounderline abstract_t">Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20:838.</a></li><li><a class="nounderline abstract_t">White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947.</a></li><li><a class="nounderline abstract_t">Theodore AC, Tseng CH, Li N, et al. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest 2012; 142:614.</a></li><li><a class="nounderline abstract_t">Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009; 136:1333.</a></li><li><a class="nounderline abstract_t">Khanna D, Yan X, Tashkin DP, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007; 56:1676.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176:1026.</a></li><li><a class="nounderline abstract_t">Furst DE, Tseng CH, Clements PJ, et al. Adverse events during the Scleroderma Lung Study. Am J Med 2011; 124:459.</a></li><li><a class="nounderline abstract_t">Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25:205.</a></li><li><a class="nounderline abstract_t">Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23:306.</a></li><li><a class="nounderline abstract_t">Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40:640.</a></li><li><a class="nounderline abstract_t">Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071.</a></li><li><a class="nounderline abstract_t">Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381:1718.</a></li><li class="breakAll">FDA. Prescribing information for Ofev (nintedanib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205832s014lbl.pdf (Accessed on November 06, 2020).</li><li><a class="nounderline abstract_t">Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 2019; 380:2518.</a></li><li><a class="nounderline abstract_t">Matteson EL, Kelly C, Distler JHW, et al. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis Rheumatol 2022; 74:1039.</a></li><li><a class="nounderline abstract_t">Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Ann Rheum Dis 2020; 79:1478.</a></li><li><a class="nounderline abstract_t">Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49:271.</a></li><li><a class="nounderline abstract_t">Goswami RP, Ray A, Chatterjee M, et al. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford) 2021; 60:557.</a></li><li><a class="nounderline abstract_t">Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 2018; 57:2106.</a></li><li><a class="nounderline abstract_t">Hoffmann-Vold AM, Maher TM, Philpot EE, et al. Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Res 2021; 7.</a></li><li><a class="nounderline abstract_t">Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 2023; 11:45.</a></li><li><a class="nounderline abstract_t">Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30:S17.</a></li><li><a class="nounderline abstract_t">Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60:578.</a></li><li><a class="nounderline abstract_t">Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40:641.</a></li><li><a class="nounderline abstract_t">Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015; 44:428.</a></li><li><a class="nounderline abstract_t">Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017; 46:625.</a></li><li><a class="nounderline abstract_t">Bernstein EJ, Peterson ER, Sell JL, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol 2015; 67:1314.</a></li><li><a class="nounderline abstract_t">Launay D, Savale L, Berezne A, et al. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Med 2014; 43:e345.</a></li><li><a class="nounderline abstract_t">Kim HJ, Tashkin DP, Gjertson DW, et al. Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. Ann Rheum Dis 2016; 75:1367.</a></li><li><a class="nounderline abstract_t">Massad MG, Powell CR, Kpodonu J, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005; 29:1510.</a></li><li><a class="nounderline abstract_t">Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54:3954.</a></li><li><a class="nounderline abstract_t">Saggar R, Khanna D, Furst DE, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010; 36:893.</a></li><li><a class="nounderline abstract_t">Miele CH, Schwab K, Saggar R, et al. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. Ann Am Thorac Soc 2016; 13:793.</a></li><li><a class="nounderline abstract_t">Crespo MM, Bermudez CA, Dew MA, et al. Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes. Ann Am Thorac Soc 2016; 13:784.</a></li><li><a class="nounderline abstract_t">Sottile PD, Iturbe D, Katsumoto TR, et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation 2013; 95:975.</a></li><li><a class="nounderline abstract_t">Chan EY, Goodarzi A, Sinha N, et al. Long-Term Survival in Bilateral Lung Transplantation for Scleroderma-Related Lung Disease. Ann Thorac Surg 2018; 105:893.</a></li><li><a class="nounderline abstract_t">Fernández-Codina A, Berastegui C, Pinal-Fernández I, et al. Lung transplantation in systemic sclerosis: A single center cohort study. Joint Bone Spine 2018; 85:79.</a></li><li><a class="nounderline abstract_t">Pradère P, Tudorache I, Magnusson J, et al. Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. J Heart Lung Transplant 2018; 37:903.</a></li><li><a class="nounderline abstract_t">Khan IY, Singer LG, de Perrot M, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med 2013; 107:2081.</a></li><li><a class="nounderline abstract_t">Rizzi M, Sarzi-Puttini P, Airoldi A, et al. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease. Clin Exp Rheumatol 2015; 33:S142.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Volkmann ER, Tseng CH, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 2016; 75:374.</a></li><li><a class="nounderline abstract_t">Katzen JB, Raparia K, Agrawal R, et al. Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study. PLoS One 2015; 10:e0117829.</a></li><li><a class="nounderline abstract_t">Goldin JG, Kim GHJ, Tseng CH, et al. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc 2018; 15:1286.</a></li><li><a class="nounderline abstract_t">Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179:408.</a></li><li><a class="nounderline abstract_t">Richardson C, Agrawal R, Lee J, et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. Semin Arthritis Rheum 2016; 46:109.</a></li><li><a class="nounderline abstract_t">Miura Y, Saito T, Fujita K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:235.</a></li><li><a class="nounderline abstract_t">Khanna D, Albera C, Fischer A, et al. Safety and tolerability of pirfenidone in patients with systemic sclerosis-associated interstitial lung disease – the Lotuss study. Ann Rheum Dis 2015; 74:816.</a></li><li><a class="nounderline abstract_t">Safety And Tolerability Of Pirfenidone In Patients With Systemic Sclerosis-Associated Interstitial Lung Disease - The LOTUSS Study. Am J Respir Crit Care Med 2015; 191:A1175.</a></li><li><a class="nounderline abstract_t">de Paoli FV, Nielsen BD, Rasmussen F, et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 2014; 43:342.</a></li><li><a class="nounderline abstract_t">Khanna D, Spino C, Johnson S, et al. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol 2020; 72:125.</a></li><li><a class="nounderline abstract_t">Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378:35.</a></li><li><a class="nounderline abstract_t">van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311:2490.</a></li><li><a class="nounderline abstract_t">Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378:498.</a></li><li><a class="nounderline abstract_t">ASHBA JK, GHANEM MH. THE LUNGS IN SYSTEMIC SCLEROSIS. Dis Chest 1965; 47:52.</a></li><li><a class="nounderline abstract_t">Guttadauria M, Diamond H, Kaplan D. Colchicine in the treatment of scleroderma. J Rheumatol 1977; 4:272.</a></li><li class="breakAll">Sackner MA. Scleroderma. In: Modern Medical Monographs, Grune and Stratton, New York 1966. Vol 26, p.76.</li><li><a class="nounderline abstract_t">CONNER PK, BASHOUR FA. Cardiopulmonary changes in scleroderma. A physiologic study. Am Heart J 1961; 61:494.</a></li><li><a class="nounderline abstract_t">Steen VD, Owens GR, Redmond C, et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28:882.</a></li><li><a class="nounderline abstract_t">Böni A, Pavelka K, Kludas M. [Treatment of progressive scleroderma with D-penicillamine (Metalcaptase)]. Munch Med Wochenschr 1969; 111:1580.</a></li><li><a class="nounderline abstract_t">de Clerck LS, Dequeker J, Francx L, Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum 1987; 30:643.</a></li><li><a class="nounderline abstract_t">Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42:1194.</a></li><li><a class="nounderline abstract_t">HUGHES DT, LEE FI. Lung function in patients with systemic sclerosis. Thorax 1963; 18:16.</a></li><li><a class="nounderline abstract_t">Kallenberg CG, Jansen HM, Elema JD, The TH. Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest 1984; 86:489.</a></li><li><a class="nounderline abstract_t">NICE CM Jr, MENON AN, RIGLER LG. Pulmonary manifestations in collagen diseases. Am J Roentgenol Radium Ther Nucl Med 1959; 81:264.</a></li><li><a class="nounderline abstract_t">Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148:1076.</a></li><li><a class="nounderline abstract_t">Rossi GA, Bitterman PB, Rennard SI, et al. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 1985; 131:612.</a></li><li><a class="nounderline abstract_t">SULLIVAN MA, MILLER DK. Pulmonary manifestations in collagen disease. Arch Intern Med 1962; 110:769.</a></li><li><a class="nounderline abstract_t">Dines DE. Pulmonary disease of vascular origin. Dis Chest 1968; 54:3.</a></li><li><a class="nounderline abstract_t">Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014; 146:422.</a></li><li><a class="nounderline abstract_t">Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021; 80:219.</a></li><li><a class="nounderline abstract_t">Volkmann ER, Tashkin DP, Silver R, et al. Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials. Lancet Rheumatol 2022; 4:e668.</a></li><li><a class="nounderline abstract_t">Champtiaux N, Cottin V, Chassagnon G, et al. Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. Semin Arthritis Rheum 2019; 49:98.</a></li></ol></div><div id="topicVersionRevision">Topic 4375 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24838199" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18706680" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Determinants of morbidity and mortality of systemic sclerosis in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19180517" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316389" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22213733" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16224252" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : New developments in scleroderma interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329309" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Changes in causes of death in systemic sclerosis, 1972-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12070056" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218621" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26564810" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Idiopathic non-specific interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24127020" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266451" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interstitial lung disease in connective tissue disease--mechanisms and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083266" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Severe organ involvement in systemic sclerosis with diffuse scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25709096" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23065360" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24591477" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prediction of pulmonary complications and long-term survival in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7945491" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21618205" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30275265" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30409830" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31310156" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18369202" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Interstitial lung disease in systemic sclerosis: a simple staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28629914" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530640" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694236" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901414" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790698" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cyclophosphamide versus placebo in scleroderma lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27469583" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157146" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490756" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840379" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881859" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295413" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20532938" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467932" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17822892" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071023" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24864029" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27049330" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28376288" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31813058" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17136984" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378460" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378460" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27156934" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29066464" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32866440" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34851799" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133610" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21547897" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937831" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9676764" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11950014" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15485010" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18078622" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18464307" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336309" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858177" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156609" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892673" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469162" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17717203" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531236" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Adverse events during the Scleroderma Lung Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16228107" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15293090" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Experience with azathioprine in systemic sclerosis associated with interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23457378" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836310" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566307" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566307" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31112379" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35199968" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32759258" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447770" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33164098" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30053212" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33644224" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36375479" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22244622" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19180481" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282550" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25300701" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27839742" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581250" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25027464" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26757749" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16222454" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Outcomes of lung transplantation in patients with scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133609" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351032" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Systemic sclerosis and bilateral lung transplantation: a single centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27078625" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26669584" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545509" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Outcomes in systemic sclerosis-related lung disease after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29394994" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Long-Term Survival in Bilateral Lung Transplantation for Scleroderma-Related Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28408277" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lung transplantation in systemic sclerosis: A single center cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29628135" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24113572" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Survival after lung transplantation in systemic sclerosis. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26339893" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452309" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25689302" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30265153" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19096004" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27033049" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25363224" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Safety and tolerability of pirfenidone in patients with systemic sclerosis-associated interstitial lung disease–the Lotuss study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Safety And Tolerability Of Pirfenidone In Patients With Systemic Sclerosis-Associated Interstitial Lung Disease - The LOTUSS Study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088011" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Abatacept induces clinical improvement in patients with severe systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31342624" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29298160" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25058083" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777972" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14254163" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : THE LUNGS IN SYSTEMIC SCLEROSIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/926103" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Colchicine in the treatment of scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/926103" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Colchicine in the treatment of scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13695062" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Cardiopulmonary changes in scleroderma. A physiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026885" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The effect of D-penicillamine on pulmonary findings in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5394493" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : [Treatment of progressive scleroderma with D-penicillamine (Metalcaptase)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3606683" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10366112" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13955537" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Lung function in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6468014" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13617550" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Pulmonary manifestations in collagen diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214928" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3994157" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13979206" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Pulmonary manifestations in collagen disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4385701" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Pulmonary disease of vascular origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24576924" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32988845" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37745675" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30409416" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
